Featured Research

from universities, journals, and other organizations

New Internet Site Tracks Antibiotic Resistance Trends

Date:
February 20, 1998
Source:
Noonan/Russo Communications
Summary:
For the first time, physicians and medical researchers around the world can use the Internet to track trends in bacterial resistance to utilization trends of prescription antibiotics.

The Resistance Web ™, developed by The Clinical Pharmacokinetics Laboratory (CPL) at the Millard Fillmore Hospital in Buffalo, NY, offers health care professionals and medical researchers immediate access to the results of 10 years of drug resistance tracking and associated drug utilization data and demographic information. The site will help to alert medical professionals to drug resistance patterns, the dangers of over-prescribing antibiotics and to encourage increased focused surveillance activities.

"We have intuitively known for many years that improper drug usage will impact the levels of bacterial resistance in our community," said Jerome J. Schentag, Pharm. D., Director of the CPL and a faculty member of the State University of New York (SUNY) at Buffalo School of Pharmacy, who has studied the relationship between antibiotic use and microbial resistance for more than 20 years. "Analyzing bacterial resistance trends with antibiotic utilization may be the key to a better understanding of how we as researchers and clinicians can modify our prescribing habits to slow the increase in resistance to commonly prescribed antibiotics. Resistance Web ™ is an important tool to raise awareness of the seriousness of this matter."

The site houses a powerful database enabling the user to construct customized queries on susceptibility patterns of different bacteria to specific antibiotics, regionally and nationally. The database is accessible to health care professionals, including infection control professionals, infectious disease specialists, pharmacists and medical researchers.

Resistance Web™ offers access to susceptibility data and patterns for clinical bacterial isolates gathered through surveillance and benchmarking studies conducted by the CPL since 1988. Analysis reports of the database's information, conducted regularly by CPL researchers, will be posted on the website and sent via email to its members. To ensure that Resistance Web™ is as comprehensive as possible, institutions are encouraged to submit their own data for review and potential uploading to the database.

Tracking a Trend

For example, a critical care specialist in a community hospital with an emerging resistance problem in the medical intensive care unit can log-in to the CPL trends database and run a query to investigate the relationship between the use of various types of antibiotics, indicated on the site by generic name, and the bacteria's historical rate of susceptibility to those antibiotics.

"The site's rapid delivery of information is a major advancement in the effort to prolong the life of viable antibiotics," said Dr. Schentag. "It takes seven to 10 years to develop a new antibiotic and bacteria just a few months or years to develop resistance to it. Currently the medical world is faced with a significant lag between the time that surveillance studies of resistance are done and the time that the information is presented to the medical community. We're simply using the web's immediacy to speed the process between identifying a resistance problem and reacting to it."

The site's database is divided into two major categories, one that tracks trend data and another that reports results of spot surveillance studies. Registered members can go on-line to locate specific information relevant to their area of interest. Trend data are composed of yearly information matched with antibiotic use information and are updated quarterly. Spot surveillance studies investigate the activity of various panels of antibiotics versus a defined sample of clinical bacterial isolates collected for a specified period of time.

The multi-hospital, Millard Fillmore Health System (MFHS), and the State University of New York at Buffalo School of Pharmacy established the Clinical Pharmacokinetics Laboratory (CPL) as a joint venture in 1972. Since then, the CPL has matured into a multidisciplinary health care research center with more than 75 full-time and 15 part-time employees. The CPL sponsors fellowship training in clinical pharmacokinetics and pharmacodynamics, infectious diseases, clinical pharmacology, and pharmacometrics. Rhτne-Poulenc Rorer Pharmaceuticals Inc. provides initial funding for the Resistance Web ™ project through an unrestricted educational grant.


Story Source:

The above story is based on materials provided by Noonan/Russo Communications. Note: Materials may be edited for content and length.


Cite This Page:

Noonan/Russo Communications. "New Internet Site Tracks Antibiotic Resistance Trends." ScienceDaily. ScienceDaily, 20 February 1998. <www.sciencedaily.com/releases/1998/02/980220064054.htm>.
Noonan/Russo Communications. (1998, February 20). New Internet Site Tracks Antibiotic Resistance Trends. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1998/02/980220064054.htm
Noonan/Russo Communications. "New Internet Site Tracks Antibiotic Resistance Trends." ScienceDaily. www.sciencedaily.com/releases/1998/02/980220064054.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins